VIVUS Announces it will Provide Telehealth to Patients through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth
CAMPBELL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced it has entered into a strategic partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company. The program, titled “VIVUS Engage,” will establish a robust online telemedicine platform for the distribution of QSYMIA® (phentermine and topiramate extended-release capsules CIV), the leading non-injectable branded weight loss medication in the U.S. for adults.
- Under the terms of the agreement, UpScript LLC will make QSYMIA available to patients through its proprietary Telehealth Platform.
- With over 20 years of experience and more than one million patients served, UpScriptHealth specializes in creating effective web-based campaigns for pharmaceutical companies.
- For patients actively seeking online support and solutions, UpScriptHealth offers a fast and convenient option.
- Combined with a healthy diet and exercise, it has been proven to help patients lose weight and maintain weight loss.